window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 3 clinical trial

  • Biologics & Biosimilars,Biomanufacturing,Biotech,Clinical Development,Clinical Trials,Drug approval,Drug Development,FDA,Rare Diseases,Research & Development

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    February 19, 2026
  • Biomanufacturing,Cardiovascular diseases,Cell & Gene Therapy,Clinical Development

    CellProthera acquires full rights to transendocardial catheter from Celyad Oncology

    CellProthera has acquired full rights to the transendocardial catheter originally [...]

    February 15, 2026
  • Central Nervous System,Chronic diseases,Clinical Development,Clinical Trials,Drug Delivery & Formulation,Drug Development,Pharmaceuticals and therapeutics,Respiratory

    Positive Phase 3 KALOS and LOGOS trial results for Breztri published in The Lancet Respiratory Medicine

    Full results from the Phase 3 KALOS and LOGOS trials [...]

    February 13, 2026
  • Clinical Trials,Dermatology,Drug Development,European biotech,Pharmaceuticals and therapeutics

    Almirall to launch phase 3 LumiNE study of lebrikizumab in nummular eczema

    Almirall has announced plans to initiate a phase 3 clinical [...]

    January 15, 2026
  • Central Nervous System,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics

    Celon Pharma receives FDA clearance for Phase 3 trial of CPL’36 in schizophrenia

    Celon Pharma S.A. has received FDA clearance to advance its [...]

    October 8, 2025
  • Biologics & Biosimilars,Chronic diseases,Clinical Development,Clinical Trials,Drug Development,Global health,Medical devices,Pharmaceuticals and therapeutics,Regulatory Affairs

    Hansa Biopharma reports statistically significant improvement in kidney function, supporting planned BLA submission

    Hansa Biopharma AB has announced positive topline results from the [...]

    September 26, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Clinical Trials

    CellProthera taps CELLforCURE by SEQENS for phase 3 production of heart attack cell therapy

    First clinical batches of ProtheraCytes expected in 2026 CellProthera has [...]

    May 27, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed
    Categories: Clinical Trials, Immunology, Oncology, Research & Development
  • Chemify founder publishes three papers on programmable chemistry and automated drug discovery
    Categories: Artificial Intelligence, Drug discovery, Research & Development, Technology and platforms
  • European liver experts highlight rising MASLD burden at EASL symposium in Budapest
    Categories: Clinical studies, Gastroenterology, Healthcare leadership, Liver disease, Metabolic Diseases
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top